{"disease":{"id":"plasma-cell-leukemia-pcl","name":"plasma cell leukemia pcl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07185490","title":"IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07085559","title":"Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT07509086","title":"IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}